 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
OXC4T4-302
NCT00507429
|
|
| |
Vandetanib in Treating Young Patients With Medullary Thyroid Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
NCI-07-C-0189
07-C-0189, NCT00514046
|
|
| |
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
JHOC-J0459
JHOC-04080402, NCT00100828
|
|
| |
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
|
|
|
|
Phase II
|
|
|
|
MDA-2004-0059
6132, NCI-6132, NCT00104871
|
|
| |
17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
MAYO-MC0476
6482, NCI-6482, NCT00118248, JHOC-JS0652, JHOC-B/06/174
|
|
| |
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
CASE-5304
7037, NCI-7037, NCT00126568
|
|
| |
Lenalidomide in Treating Patients With Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine and Cannot Be Removed By Surgery
|
|
|
|
Phase II
|
|
|
|
UKMC-05-0701-F3R
CELGENE-UKMC-05-0701-F3R, NCT00287287
|
|
| |
Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
|
|
|
|
Phase II
|
|
|
|
UCCRC-14696A
14696A, 7735, NCI-7735, NCT00381641
|
|
| |
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
OSU-06054
7609, NCI-7609, NCT00390325
|
|
| |
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
|
|
|
|
Phase II
|
|
|
|
A4061027
NCT00389441
|
|
